Livmoniplimab, ATEZOLIZUMAB, TREMELIMUMAB, BEVACIZUMAB, Budigalimab, IMFINZI 50 mg/mL concentrate for solution for infusion.
M24-052
Phase 3 small_molecule active
Quick answer
Livmoniplimab, ATEZOLIZUMAB, TREMELIMUMAB, BEVACIZUMAB, Budigalimab, IMFINZI 50 mg/mL concentrate for solution for infusion. for Metastatic Hepatocellular Carcinoma (HCC) is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Metastatic Hepatocellular Carcinoma (HCC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active